Clinical Trial Goal
To find out:
- The highest dose of EB103 that's safe to give
- If EB103 is safe and works well to treat NHL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have NHL that has relapsed or is refractory. Some examples include:
- Burkitt lymphoma
- Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL)
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Mantle cell lymphoma (MCL)
- Marginal zone lymphoma (MZL)
- Precursor B-cell lymphoblastic lymphoma
- Have been treated with a monoclonal antibody that targets CD20. Your doctor can tell you this
- Do not have any of the following:
- Chronic lymphocytic leukemia
- Richter's transformation
- Do not have lymphoma in your brain or spinal cord
- Have not been treated with a drug that targets CD19. Your doctor can tell you this
- Have not allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 6 months
- Have not had autologous BMT in the last 3 months
- Do not have graft-versus-host-disease (GVHD)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
EB103 is a type of autologous T-cell therapy that targets CD19 on cancer cells.
T cells, are a type of immune cell that helps your own immune system find and destroy cancer cells.
You’ll get:
T cells, are a type of immune cell that helps your own immune system find and destroy cancer cells.
You’ll get:
- EB103 – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
The clinical trial doctors will watch you closely over 3 months. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved EB103.
Contacts
Teresa Klask, MBA, 925-949-9314, teresa.klask@eurekainc.com
Pei Wang, PhD, 510-654-7045, pei.wang@eurekainc.com
Locations
University of California, DavisRECRUITING
Sacramento, California
Contacts:
- Richard "RJ" Joven, CCRP, 916-494-2368, rmjoven@ucdavis.edu
- Dara Feleciano, RN, MSN, 916-475-9904, djfeleciano@ucdavis.edu
Baylor Scott & White Research Institute, Texas OncologyRECRUITING
Dallas, Texas
Philip Millsap, 214-820-7381, corchemebmt@BSWHealth.org
Sponsors
collaborator: Eureka Therapeutics Inc., lead: Estrella Biopharma, Inc.
